Mosaspray

Symptoms of seasonal allergic or perennial allergic rhinitis in adults & childn ≥6 yr. Symptomatic treatment of nasal polyps in adults ≥18 yr.

Seasonal allergic or perennial rhinitis Adult, elderly & childn ≥12 yr 2 actuation (50 mcg/actuation) in each nostril once daily (total dose 200 mcg), may be reduced to 1 actuation in each nostril for maintenance & may be increased to max 4 actuation in each nostril once daily. Childn 3-11 yr 1 actuation in each nostril once daily. Nasal polyposis 2 actuation (50 mcg/actuation) in each nostril once daily (total dose 200 mcg), may be increased to 2 spray in each nostril bid (total daily dose 400 mcg).

Hypersensitivity. Presence of untreated localised infection involving the nasal mucosa eg, herpes simplex. Recent nasal surgery or trauma until healing has occurred.

Caution in patients w/ active or quiescent tuberculous infections of resp tract, untreated fungal, bacterial or systemic viral infections. Risk of exposure to certain infections (eg, chickenpox, measles) in patients who are potentially immunosuppressed. Periodically examine possible changes in nasal mucosa. Discontinue if localised fungal infection of the nose or pharynx develops. Not recommended in nasal septum perforation. Epistaxis may occur. Potential systemic effects may occur particularly at high doses prescribed for prolonged periods eg, Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in childn & adolescents, cataract, glaucoma & psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in childn). Safety & efficacy has not been studied for use in the treatment of unilateral polyps, polyps associated w/ cystic fibrosis, or polyps that completely obstruct the nasal cavities. Reports of visual disturbances. Regularly monitor height of childn receiving prolonged treatment w/ nasal corticosteroids. Pregnancy & lactation. Infants born of mothers who received corticosteroids during pregnancy should be observed for hypoadrenalism.

Pharyngitis, URTI; headache; epistaxis, nasal burning, nasal irritation, nasal ulceration; throat irritation.

Increased risk of systemic side effects w/ CYP3A inhibitors including cobicistat-containing products.

Nasal Decongestants & Other Nasal Preparations

R01AD09 - mometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.

Rx